- Home
- MDGL vs JAZZ Comparison
MDGL vs JAZZ Comparison
Compare MDGL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- JAZZ
- Stock Information
- Founded
- MDGL 2011
- JAZZ 2003
- Country
- MDGL United States
- JAZZ Ireland
- Employees
- MDGL N/A
- JAZZ N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- JAZZ Health Care
- Exchange
- MDGL Nasdaq
- JAZZ Nasdaq
- Market Cap
- MDGL 6.8B
- JAZZ 7.3B
- IPO Year
- MDGL N/A
- JAZZ 2007
- Fundamental
- Price
- MDGL $290.18
- JAZZ $107.59
- Analyst Decision
- MDGL Strong Buy
- JAZZ Strong Buy
- Analyst Count
- MDGL 10
- JAZZ 13
- Target Price
- MDGL $420.63
- JAZZ $181.85
- AVG Volume (30 Days)
- MDGL 359.4K
- JAZZ 1.3M
- Earning Date
- MDGL 05-01-2025
- JAZZ 05-06-2025
- Dividend Yield
- MDGL N/A
- JAZZ N/A
- EPS Growth
- MDGL N/A
- JAZZ 49.21
- EPS
- MDGL N/A
- JAZZ 7.51
- Revenue
- MDGL $317,383,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- MDGL $264.55
- JAZZ $6.07
- Revenue Next Year
- MDGL $67.21
- JAZZ $4.26
- P/E Ratio
- MDGL N/A
- JAZZ $14.19
- Revenue Growth
- MDGL N/A
- JAZZ 5.76
- 52 Week Low
- MDGL $200.08
- JAZZ $95.49
- 52 Week High
- MDGL $377.46
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- MDGL 40.87
- JAZZ 46.17
- Support Level
- MDGL $280.00
- JAZZ $103.60
- Resistance Level
- MDGL $307.54
- JAZZ $108.72
- Average True Range (ATR)
- MDGL 15.83
- JAZZ 4.36
- MACD
- MDGL -2.00
- JAZZ 0.31
- Stochastic Oscillator
- MDGL 15.96
- JAZZ 40.31
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.